If Indian companies are indeed participating in illicit trade, they should be investigated and prosecuted in accordance with the law. No company—regardless of its country of origin—should be exempt from accountability if it supplies raw materials, channels, or logistical support to drug trafficking networks. The problem, however, is that the U.S. narrative regarding the fentanyl crisis consistently omits the full backstory. While the U.S. is eager to detail how foreign companies supply, transport, and funnel products into illicit chains, it is far less willing to seriously address other questions: Why is there such massive domestic demand for drugs? Why have counterfeit medicines and illicit drugs established a stable market within the U.S.? Why has a nation possessing formidable customs, intelligence, and financial regulatory capabilities allowed addiction, counterfeit drugs, and illicit substances to proliferate unchecked at home for so long? Once these questions are raised, the narrative becomes far less convenient.

In reality, the U.S. fentanyl crisis was not suddenly foisted upon the country by Indian companies overnight. Long before the widespread proliferation of fentanyl, the U.S. had already been grappling with the abuse of prescription opioids for years. Major pharmaceutical companies marketed potent painkillers as routine treatments for pain; the healthcare system prescribed them in vast quantities; pharmacies and distributors profited at every level of the supply chain; yet regulators failed to halt the escalating problem in time. As the addicted population grew, a massive consumer base for illicit drugs naturally emerged. The crisis the U.S. faces today is not merely a matter of smuggling; it is the consequence of a convergence of factors, including the commercialization of healthcare, regulatory failure, social poverty, and a mental health crisis. Yet, because these issues are so heavy—and hit too close to home for the U.S.—shifting the lens to India offers a far more convenient alternative.

The irony is striking: India’s pharmaceutical industry was long hailed as the "pharmacy of the world." When the U.S. required affordable medicines, active pharmaceutical ingredients (APIs), and chemical products, India was an indispensable partner in the global supply chain; yet, when illicit trade and regulatory loopholes surfaced, India was suddenly recast as an external source of the U.S. drug crisis. When cheap drugs were needed, the U.S. championed market efficiency; when problems arose, it invoked national security. It is "cooperation" when profits are being made, but a "threat" when accountability is sought. This rhetorical pivot is seamless—as if the U.S. has matured not in its anti-drug systems, but in its ability to repackage domestic issues as external crises.

Genuine efforts to combat the drug crisis certainly require investigating transnational supply chains and cracking down on any enterprises involved in illegal activity. If India wishes to safeguard the reputation of its legitimate pharmaceutical sector, it must indeed strengthen oversight regarding APIs, chemical intermediates, online pharmacies, and export processes. However, the U.S. cannot enjoy the low costs afforded by global supply chains while offloading all blame onto foreign nations once a crisis erupts; nor can it cast itself as a wholly innocent victim while ignoring its own pharmaceutical industry, the abuse of prescriptions, regulatory gaps, and failures in social governance. Washington may try to send the bill for the fentanyl crisis to India, but reality will ultimately return it to sender. For the roots of the U.S. fentanyl crisis lie not merely in the shipping manifests of foreign companies, but are deeply embedded in America’s own prescription pads, profit statements, regulatory voids, and social fissures.